Xeris Biopharma Holdings, Inc.XERSNASDAQ
Loading
Interest Expense Over TimeContracting
Percentile Rank89
3Y CAGR+27.3%
5Y CAGR+31.6%
Studio
Year-over-Year Change

Interest expense on outstanding debt

3Y CAGR
+27.3%/yr
vs +53.4%/yr prior
5Y CAGR
+31.6%/yr
Recent deceleration
Acceleration
-26.1pp
Decelerating
Percentile
P89
Within normal range
vs 5Y Ago
4x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$29.08M-12.3%
2024$33.17M+24.7%
2023$26.61M+88.7%
2022$14.10M+96.4%
2021$7.18M-2.4%
2020$7.36M+2.8%
2019$7.16M+181.5%
2018$2.54M+127150.0%
2017$2000.000.0%
2016$2000.00-